LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 115 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2021. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $35,270 | -5.7% | 29,890 | +12.7% | 0.00% | – |
| Q2 2023 | $37,393 | -91.1% | 26,520 | -90.5% | 0.00% | – |
| Q1 2023 | $419,654 | +2447.7% | 279,769 | +1887.1% | 0.00% | – |
| Q4 2022 | $16,472 | -3.1% | 14,079 | -9.0% | 0.00% | – |
| Q3 2022 | $17,000 | -86.6% | 15,473 | -80.7% | 0.00% | – |
| Q2 2022 | $127,000 | -35.2% | 80,169 | -37.1% | 0.00% | – |
| Q1 2022 | $196,000 | -19.0% | 127,432 | +29.2% | 0.00% | – |
| Q4 2021 | $242,000 | -1.2% | 98,659 | +1.6% | 0.00% | – |
| Q3 2021 | $245,000 | +544.7% | 97,071 | +625.8% | 0.00% | – |
| Q2 2021 | $38,000 | -91.9% | 13,374 | -93.3% | 0.00% | – |
| Q1 2021 | $467,000 | +344.8% | 198,638 | +64.3% | 0.00% | – |
| Q2 2020 | $105,000 | +94.4% | 120,899 | +84.0% | 0.00% | – |
| Q1 2020 | $54,000 | -38.6% | 65,710 | -33.5% | 0.00% | – |
| Q4 2019 | $88,000 | +100.0% | 98,833 | +119.1% | 0.00% | – |
| Q3 2019 | $44,000 | – | 45,112 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Defender Capital, LLC. | 4,735,990 | $8,335,000 | 3.63% |
| BROADWOOD CAPITAL INC | 34,005,379 | $59,849,000 | 3.55% |
| Prescott General Partners LLC | 1,851,851 | $3,259,000 | 0.14% |
| Strategic Wealth Investment Group, LLC | 66,917 | $118,000 | 0.07% |
| Laidlaw Wealth Management LLC | 170,658 | $300,000 | 0.06% |
| Humankind Investments LLC | 26,737 | $47,000 | 0.05% |
| DAFNA Capital Management LLC | 80,000 | $141,000 | 0.04% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $79,000 | 0.04% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 680,839 | $1,198,000 | 0.02% |
| Allegheny Financial Group LTD | 20,000 | $35,000 | 0.02% |